-
Alza Corporation v. IMPAX Laboratories, Inc. DC
- 3:03-cv-04032
- N.D. Cal.
- Judge: Vaughn R. Walker
- Filed: 09/04/2003
- Closed: 10/06/2005
- Latest Docket Entry: 10/04/2006
- PACER
- Docket updated daily
1
Plaintiff
1
Defendant
1
Accused
Product
1
Patent-in-Suit
764
Days in
Litigation
-
Alza Corporation v. IMPAX Laboratories, Inc. DC
- 3:03-cv-04032
- N.D. Cal.
- Judge: Vaughn R. Walker
- Filed: 09/04/2003
- Closed: 10/06/2005
- Latest Docket Entry: 10/04/2006
- PACER
- Docket updated daily
Cause of Action
Infringement
Market Sector
Biotech and Pharma
Assigned Judge
Outcome Summary
- Patent Information
-
Validity & Enforceability
Claim # | Claim Text | Outcome |
---|---|---|
1 |
A sustained-release oxybutynin formulation for oral administration to a patient comprising a therapeutic dose of an oxybutynin selected from the group consisting of oxybutynin and its pharmaceutically acceptable salt that delivers from 0 to 20% of
view more
|
Invalid
Entry 110 Entry 109 |
2 |
A sustained-release oxybutynin formulation for oral administration to a patient in need of treatment for urge incontinence comprising a therapeutic dose of an oxybutynin selected from the group consisting of oxybutynin and its pharmaceutically
view more
|
Invalid
Entry 110 Entry 109 |
3 |
A sustained-release oxybutynin solid dosage form for oral administration to a patient for treating incontinence comprising an oxybutynin selected from the group consisting of oxybutynin and its pharmaceutically acceptable salt that administers up
view more
|
Invalid
Entry 110 Entry 109 |
4 |
A sustained-release oxybutynin dosage form for oral administration to a patient for treating incontinence comprising an oxybutynin selected from the group consisting of oxybutynin and its pharmaceutically acceptable salt that administers up to 3
view more
|
Invalid
Entry 110 Entry 109 |
11 |
A method for treating incontinence in a patient, wherein the method comprises administering orally to the patient a therapeutic dose of an oxybutynin selected from the group consisting of oxybutynin and its pharmaceutically acceptable salt that
view more
|
Invalid
Entry 110 Entry 109 |
13 |
A method for treating incontinence in a patient, wherein the method comprises administering orally to the patient a therapeutic dose of an oxybutynin selected from the group consisting of oxybutynin and its pharmaceutically acceptable salt which
view more
|
Invalid
Entry 110 Entry 109 |
14 |
A method for treating incontinence in a patient, wherein the method comprises administering orally to the patient a therapeutic dose of an oxybutynin and its pharmaceutically acceptable salt, which oxybutynin is administered in up to 2 mg in 0 to
view more
|
Invalid
Entry 110 Entry 109 |
15 |
A method for treating incontinence in a patient, wherein the method comprises administering orally to the patient a therapeutic dose of an oxybutynin selected from the group consisting of oxybutynin and its pharmaceutically acceptable salt, which
view more
|
Invalid
Entry 110 Entry 109 |